Zhaoke Ophthalmology’s TAB014 Receives BLA Review for wAMD Treatment
China-based Zhaoke Ophthalmology Ltd (HKG: 6622) announced that its Biologic License Application (BLA) for TAB014,...
Tot Biopharm
Zhaoke Ophthalmology’s TAB014 Achieves Positive Phase III Results for wAMD
China-based Lee’s Pharmaceutical Holdings Ltd’s (HKG: 0950) former subsidiary, Zhaoke Ophthalmology Ltd (HKG: 6622), has...
Shanghai Escugen Partners with Foreseen Biotechnology for ADC Development
China-based Shanghai Escugen has entered into a partnership with domestic firm Foreseen Biotechnology to develop...
Tot Biopharmaceutical and GL-Biotech Collaborate on DisacLink Technology for ADC Advancements
China-based Tot Biopharma International Co., Ltd (HKG: 1875) has announced a strategic partnership with compatriot...
Tot Biopharmaceutical and Shanghai Escugen Partner on ADC Development and Commercialization
China-based Tot Biopharmaceutical International Co., Ltd (HKG: 1875) has announced a strategic partnership with Shanghai...
Tot Biopharmaceutical Partners with Suzhou Smart Nuclide on Radioactive Drug Development
China-based Tot Biopharmaceutical International Co., Ltd (HKG: 1875) has announced a strategic partnership with Suzhou...
Tot Biopharmaceutical Terminates Phase III Study for HER2-Targeted ADC TAA013
Tot Biopharmaceutical International Co., Ltd (HKG: 1875) has announced the termination of the Phase III...
Henlius’ Hanbeitai Gains NMPA Approval for Expanded Indications
Shanghai Henlius Biotech Inc. (HKG: 2696) has announced that the National Medical Products Administration (NMPA)...
Henlius Biotech’s HanBeiTai sBLA Accepted for HCC Treatment Review
Shanghai Henlius Biotech Inc. (HKG: 2696) announced that a supplementary Biologic License Application (sBLA) for...
Henlius Biotech’s HanBeiTai Biosimilar of Avastin Accepted for CDE Review
Shanghai Henlius Biotech Inc. (HKG: 2696) announced that the Center for Drug Evaluation (CDE) has...
Zhaoke Ophthalmology Enrolls First Patient in TAB014 Phase III Study for wAMD
Lee’s Pharmaceutical Holdings Ltd’s (HKG: 0950) former subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622) announced the...
Kelun Pharma’s SKB264 ADC Receives Breakthrough Therapy Designation for TNBC
The Center for Drug Evaluation (CDE) website indicates that Sichuan Kelun Pharmaceutical Co., Ltd’s (SHE:...